Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

MYLK promotes hepatocellular carcinoma progression through regulating cytoskeleton to enhance epithelial–mesenchymal transition

MYLK promotes hepatocellular carcinoma progression through regulating cytoskeleton to enhance... Myosin light chain kinase (MYLK) is found to catalyze the phosphorylation of myosin light chains (MLC) and regulate invasion and metastasis in some malignancies. However, there is little knowledge on the role of MYLK in hepatocellular carcinoma (HCC), and no studies have been conducted to investigate the mechanisms underlying MYLK-mediated promotion of HCC invasion and metastasis until now. In this study, we investigated the expression of MYLK in 50 pairs of human HCC and adjacent liver specimens. High MYLK expression was significantly correlated with aggressive clinicopathological features including tumor encapsulation, microvascular invasion and metastasis. In vitro assays showed that shRNA-induced MYLK knockdown significantly inhibited the wound-healing ability of HCC cells and the ability to migrate and invade through Matrigel. We next uncovered that MYLK knockdown resulted in a reduction in the number of F-actin stress fibers, disorganization of F-actin architectures and morphological alterations of HCC cells. Phosphorylated MLC, rather than total MLC, was found to be markedly reduced in response to downregulation of MYLK expression, and MYLK-regulated actin cytoskeleton through phosphorylating MLC in HCC cells. In addition, Western blotting assay revealed downregulation of the epithelial marker E-cadherin and upregulation of mesenchymal markers Vimentin, N-cadherin and Snail. Taken together, our findings indicate that MYLK promotes HCC progression by altering cytoskeleton to enhance epithelial–mesenchymal transition (EMT). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Experimental Medicine Springer Journals

MYLK promotes hepatocellular carcinoma progression through regulating cytoskeleton to enhance epithelial–mesenchymal transition

Download PDF
11 pages

Loading next page...
 
/lp/springer_journal/mylk-promotes-hepatocellular-carcinoma-progression-through-regulating-0Rw7qZ93Ph
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Internal Medicine; Hematology; Oncology
ISSN
1591-8890
eISSN
1591-9528
DOI
10.1007/s10238-018-0509-2
Publisher site
See Article on Publisher Site

Abstract

Myosin light chain kinase (MYLK) is found to catalyze the phosphorylation of myosin light chains (MLC) and regulate invasion and metastasis in some malignancies. However, there is little knowledge on the role of MYLK in hepatocellular carcinoma (HCC), and no studies have been conducted to investigate the mechanisms underlying MYLK-mediated promotion of HCC invasion and metastasis until now. In this study, we investigated the expression of MYLK in 50 pairs of human HCC and adjacent liver specimens. High MYLK expression was significantly correlated with aggressive clinicopathological features including tumor encapsulation, microvascular invasion and metastasis. In vitro assays showed that shRNA-induced MYLK knockdown significantly inhibited the wound-healing ability of HCC cells and the ability to migrate and invade through Matrigel. We next uncovered that MYLK knockdown resulted in a reduction in the number of F-actin stress fibers, disorganization of F-actin architectures and morphological alterations of HCC cells. Phosphorylated MLC, rather than total MLC, was found to be markedly reduced in response to downregulation of MYLK expression, and MYLK-regulated actin cytoskeleton through phosphorylating MLC in HCC cells. In addition, Western blotting assay revealed downregulation of the epithelial marker E-cadherin and upregulation of mesenchymal markers Vimentin, N-cadherin and Snail. Taken together, our findings indicate that MYLK promotes HCC progression by altering cytoskeleton to enhance epithelial–mesenchymal transition (EMT).

Journal

Clinical and Experimental Medicine – Springer Journals

Published: May 31, 2018

References

  • Hallmarks of cancer: the next generation
    Hanahan, D; Weinberg, RA
  • Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer
    Kelley, LC; Shahab, S; Weed, SA
  • Targeting calcium signaling in cancer therapy
    Cui, C; Merritt, R; Fu, L; Pan, Z
  • Myosin Light Chain Kinase MYLK1: anatomy, Interactions, Functions, and Regulation
    Khapchaev, AY; Shirinsky, VP
  • Phosphorylation of myosin light chain kinase: a cellular mechanism for Ca2+ desensitization
    Stull, JT; Tansey, MG; Tang, DC; Word, RA; Kamm, KE
  • Directed migration of cancer cells guided by the graded texture of the underlying matrix
    Park, J; Kim, DH; Kim, HN; Wang, CJ; Kwak, MK; Hur, E
  • Myosin light chain kinase is responsible for high proliferative ability of breast cancer cells via anti-apoptosis involving p38 pathway
    Cui, WJ; Liu, Y; Zhou, XL; Wang, FZ; Zhang, XD; Ye, LH
  • MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data
    Tan, X; Chen, M
  • Androgens down-regulate myosin light chain kinase in human prostate cancer cells
    Leveille, N; Fournier, A; Labrie, C
  • Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer
    Chen, L; Su, L; Li, J; Zheng, Y; Yu, B; Yu, Y
  • Integrin beta1, myosin light chain kinase and myosin IIA are required for activation of PI3 K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer
    Choi, C; Kwon, J; Lim, S; Helfman, DM
  • The ZEB1/miR-200c feedback loop regulates invasion via actin interacting proteins MYLK and TKS5
    Sundararajan, V; Gengenbacher, N; Stemmler, MP; Kleemann, JA; Brabletz, T; Brabletz, S
  • All-Trans Retinoic Acid Inhibits Human Colorectal Cancer Cells RKO Migration via Downregulating Myosin Light Chain Kinase Expression through MAPK Signaling Pathway
    Zuo, L; Yang, X; Lu, M; Hu, R; Zhu, H; Zhang, S
  • Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling
    Kim, DY; Helfman, DM
  • Matrine inhibits diethylnitrosamine-induced HCC proliferation in rats through inducing apoptosis via p53, Bax-dependent caspase-3 activation pathway and down-regulating MLCK overexpression
    Zhang, X; Yu, H
  • 220- and 130-kDa MLCKs have distinct tissue distributions and intracellular localization patterns
    Blue, EK; Goeckeler, ZM; Jin, Y; Hou, L; Dixon, SA; Herring, BP
  • Tumor progression and metastasis
    Yokota, J
  • Epithelial-mesenchymal transition in cancer development and its clinical significance
    Iwatsuki, M; Mimori, K; Yokobori, T; Ishi, H; Beppu, T; Nakamori, S
  • Tumor Stiffness Is Unrelated to Myosin Light Chain Phosphorylation in Cancer Cells
    Yu, HJ; Serebryannyy, LA; Fry, M; Greene, M; Chernaya, O; Hu, WY
  • Melatonin inhibits the migration of colon cancer RKO cells by down-regulating myosin light chain kinase expression through cross-talk with p38 MAPK
    Zou, DB; Wei, X; Hu, RL; Yang, XP; Zuo, L; Zhang, SM
  • A novel all-trans retinoid acid derivatives inhibits the migration of breast cancer cell lines MDA-MB-231 via myosin light chain kinase involving p38-MAPK pathway
    Wang, B; Yan, Y; Zhou, J; Zhou, Q; Gui, S; Wang, Y; Wang, Y
  • Mechanisms of motility in metastasizing cells
    Yilmaz, M; Christofori, G
  • The actin cytoskeleton in cancer cell motility
    Olson, MF; Sahai, E
  • Actin binding proteins: their ups and downs in metastatic life
    Gross, SR
  • EMT, the cytoskeleton, and cancer cell invasion
    Yilmaz, M; Christofori, G
  • Biomarkers for epithelial-mesenchymal transitions
    Zeisberg, M; Neilson, EG